BeiGene ADR had its Relative Strength (RS) Rating upgraded from 70 to 75 Monday — a welcome improvement, but still below the 80 or better score you prefer to see.
IBD's proprietary rating measures share price action with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the trailing 52 weeks stacks up against all the other stocks in our database.
Decades of market research reveals that the market's biggest winners typically have an 80 or higher RS Rating in the early stages of their moves. See if BeiGene ADR can continue to show renewed price strength and hit that benchmark.
How To Invest In Stocks In Both Bull And Bear Markets
BeiGene ADR is working on a consolidation with a 248.16 entry. See if the stock can break out in volume at least 40% higher than normal.
The company showed 0% EPS growth in its most recent report, while sales growth came in at 28%.
The company holds the No. 148 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Corcept Therapeutics and Catalyst Pharmaceuticals are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Technical Action?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
